Wed, Jan 10, 2024
Lupin said that it was the exclusive first-to-file for Bromfenac Ophthalmic Solution, 0.07%, and is eligible for 180-day exclusivity.
More >
Thu, Jan 04, 2024
Stocks to watch on Friday, January 5: Lupin got a receipt of tentative approval from the U.S. Food and Drugs Administration (USFDA) for Dapagliflozin and Saxagliptin tablets.
Tue, Jan 02, 2024
At around 9:55 a.m., shares of Lupin traded up by 4.51 per cent or Rs 59.2 at Rs 1371.85 apiece. The market capitalisation of the pharmaceutical company stood at Rs 62,457.14 crore at the same time.
Fri, Oct 07, 2022
"Through this, we will further reinforce our long legacy to provide shorter, more patient-friendly treatment options to prevent TB," Lupin Managing Director Nilesh Gupta said in a statement.
Tue, Oct 04, 2022
Lupin will also potentially have shared 180-day exclusivity on the 600 mg tablets.
Fri, Sep 30, 2022
Lupin share price on Friday jumped over 4 per cent as it received the US FDA nod for manufacturing a new drug to treat overactive bladder at the company's facility in Nagpur.
Thu, Sep 29, 2022
Received warning letter for Tarapur plant from US FDA. The plant was investigated from March 22 to April 4. Will address US FDA concerns soon: Lupin.
Thu, Aug 04, 2022
What should be the caution today in lupin? Which companies produced poor results? Why focus on fertilizer chemical companies? Know the analysis of June quarter results from Anil Singhvi.
Wed, Mar 02, 2022
Certain stocks were in action in either direction based on reports linked to them. Here is a list of some of such stocks.
Tue, Feb 08, 2022
Indian market snapped a three-day losing streak and closed in positive on Tuesday.
Mon, Feb 07, 2022
Rakesh Jhunjhunwala–backed Lupin shares touched a new 52-week low to Rs 806.05 per share, slipping by 7.5 per cent on the BSE on the intraday basis on Monday.
Fri, Feb 04, 2022
In Q3FY22, the drugmaker’s EBITDA (earnings before interest tax and depreciation and amortization) margins dipped by 580 basis points (bps) sequentially, 1,050 bps year-on-year (YoY) to 9.9 per cent.
In line with the announcements of quarterly earnings results in this season Drugmaker Lupin on Friday reported a 24.45 per cent rise in its consolidated net profit at Rs 545.5 crore for the third quarter ended December 31. Here are key highlights of the result
Fri, Dec 24, 2021
Homegrown pharmaceuticals major Lupin on Friday said it has received tentative approval from the US health regulator for its generic Azilsartan Medoxomil tablets used to treat high blood pressure.
Fri, Dec 10, 2021
Homegrown pharma major Lupin Ltd on Friday announced the launch of its diagnostics arm as part of its strategy to provide integrated healthcare in India.
Thu, Dec 02, 2021
Pharma major Lupin Ltd on Thursday said its wholly-owned arm Lupin Inc has inked a pact with TTP Plc to acquire exclusive worldwide rights to develop, manufacture and commercialise inhalation products, using the latter's soft-mist inhalation technology platform.
Tue, Oct 12, 2021
The Nifty Auto was trading at 11,454.80 and was up almost 0.70 per cent. In the 15-share index, 11 advanced and 4 declined around this time. The biggest gainers were Bajaj Auto Limited, TVS Motor Company Limited, and Eicher Motors Limited and were up 3.2 per cent, 2.8 per cent and 2.6 per cent, respectively
Thu, Sep 30, 2021
Cardiovascular disease (CVD) is the leading cause of mortality and accounts for one-third of global deaths. Cardiac has displaced anti-infectives as the leading therapy in the India Pharma Market (IPM).
Wed, Sep 29, 2021
Sun Pharmaceuticals – The shares of Sun Pharma today ended at Rs 790.50 on Tuesday, up 3.6 per cent from the Monday closing price. He puts target price at Rs 850-Rs 880 with a stop loss at Rs 755. The stock has seen some correction after attaining a 52-week high of Rs 804.35 on 3 August
Wed, Aug 11, 2021
The shares of Lupin on Wednesday slumped by around 7 per cent to Rs 1043.15 a share on the BSE intraday trade today, despite good but below street’s expectations first-quarter numbers yesterday
Tue, Jun 15, 2021
Zee Business Research Analyst Ashish Chaturvedi explaining the brokerages' stance for various stocks on Tuesday said that bumper returns are expected from most of these shares.
Sun, Jun 13, 2021
Drug firm Lupin on Sunday said it has received a warning letter from the US health regulator for its Somerset facility in the US. The United States Food and Drug Administration (USFDA) had inspected the company's Somerset, New Jersey, facility from September 10, 2020, to November 5, 2020, Lupin said in a regulatory filing
Wed, Jun 02, 2021
Rakesh Jhunjhunwala stocks Portfolio: As per the latest corporate shareholdings filed on BSE, Rakesh Jhunjhunwala publicly holds 37 stocks with a net worth of over Rs 18260 cr. He holds 1.6% stake in Titan (72.5 lkr shares) worth Rs 907 cr. Lupin is nearly 5% of the Big Bull’s Portfolio. Lupin share price today is Rs 1263, up Rs 52 or 4.4%
By accepting cookies, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
